Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by investment analysts at Piper Jaffray Companies in a report issued on Tuesday, November 26th, TipRanks reports. They currently have a $104.00 target price on the stock. Piper Jaffray Companies’ target price indicates a potential upside of 59.66% from the stock’s previous close. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($1.20) EPS, Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.
A number of other equities research analysts have also weighed in on the stock. Barclays lifted their target price on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Finally, BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $69.54.
Shares of CRSP stock opened at $65.14 on Tuesday. The business has a 50-day moving average of $61.79 and a 200 day moving average of $49.31. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a market capitalization of $3.64 billion, a PE ratio of -18.94 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares in the last quarter. ARK Investment Management LLC boosted its holdings in Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares in the last quarter. Wells Fargo & Company MN increased its stake in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Crispr Therapeutics during the third quarter valued at about $21,167,000. Institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is the S&P/ASX 200 Index?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.